Vowst denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vowst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Blue Cross Blue Shield Denied Vowst as "Experimental"

Vowst (fecal microbiota, live-jslm) received FDA approval for the prevention of recurrent Clostridioides difficile (C. diff) infection. An "experimental or investigational" denial from BCBS typically means the plan's coverage policy has not yet been updated to reflect FDA approval, the plan is applying an outdated policy that predates approval, or BCBS is alleging the use falls outside the approved indication.

For an FDA-approved drug used for its approved indication, an "experimental" denial is one of the most legally vulnerable positions an insurer can take.

## Why This Denial Is Appealable

FDA approval is the statutory standard for non-experimental status under most plan documents and many state insurance laws. If Vowst is being prescribed for its FDA-approved indication, BCBS's experimental classification is directly contradicted by the regulatory record.

• ACA §2719 external review: Independent external reviewers routinely overturn experimental denials when the drug holds FDA approval for the indication at issue. File within approximately four months of your internal denial notice.
• ACA medical necessity protections: Grandfathered plan or not, the plan's definition of "experimental" must be applied consistently. FDA-approved drugs are generally excluded from experimental classification by the plan's own definition.
• ERISA §503 (employer plans): You are entitled to the complete clinical policy and the clinical reviewer's rationale — request both.
• State coverage mandates: Some states have laws specifically prohibiting classification of FDA-approved drugs as experimental. Check whether your state's law applies.
• Expedited review: Available if C. diff recurrence risk makes delay medically urgent.

## Documentation to Gather

• FDA approval documentation: Print the FDA approval letter and the current prescribing label from DailyMed. Confirm the indication matches the prescribed use.
• BCBS's experimental/investigational policy: Request the specific written policy BCBS applied. Identify whether it defines "experimental" in a way that excludes FDA-approved drugs.
• Prescriber medical-necessity letter: The physician should confirm the prescribed indication matches the FDA-approved use, document the C. diff recurrence history, and state why Vowst is medically necessary.
• C. diff treatment and recurrence history: Lab-confirmed episodes with dates, antibiotic courses used, and outcomes — establishing the clinical context for prevention.

## Criteria-Mapping Approach

| BCBS experimental-denial basis | Your response | |---|---| | Drug lacks sufficient evidence | FDA approval letter + approved label (FDA is the national evidence standard) | | Use is investigational | Confirmation that prescribed indication matches approved label indication | | Plan policy excludes category | BCBS's own policy language defining experimental — show FDA-approved drugs are excluded |

## Next Step

File a written internal appeal leading with the FDA approval documentation. Request that BCBS identify, in writing, any remaining basis for the experimental classification after reviewing the FDA approval letter. If denied internally, file for external review immediately — this is a strong external-review case.